Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
This study showed that the incidence of a first episode of grade ≥3 irAE was 15.0% (95% CI: 9.6% to 22.9%) at 1 year and the cumulative incidence of all severe irAE episodes was 26.9 per 100 person-years. Low CD4 count, positive CMV serology, history of cancer surgery and a longer time since HIV diagnosis were associated with the occurrence of severe irAEs.
Authors
- Thierry Allègre
- Christine Katlama (ORCID: https://orcid.org/0000-0002-5093-4800)
- Jean‐Philippe Spano (ORCID: https://orcid.org/0000-0002-3921-2479)
- Olivia Zaegel‐Faucher (ORCID: https://orcid.org/0000-0003-4223-1467)
- A. Lavolé
- Dominique G. Costagliola (ORCID: https://orcid.org/0000-0003-0765-0869)
- Anne‐Geneviève Marcelin (ORCID: https://orcid.org/0000-0003-4808-8999)
- Pierre Delobel (ORCID: https://orcid.org/0000-0002-2874-3581)
- Kévin Bihan (ORCID: https://orcid.org/0000-0001-6797-0237)
- Séverine Gibowski
- Laurent Greillier (ORCID: https://orcid.org/0000-0002-5807-9503)
- Baptiste Abbar (ORCID: https://orcid.org/0000-0002-5907-8131)
- Marine Baron (ORCID: https://orcid.org/0000-0003-0212-8684)
- Marianne Veyri (ORCID: https://orcid.org/0000-0002-7020-8160)
- Alain Makinson (ORCID: https://orcid.org/0000-0003-2817-8444)
- Michèle Genin
- Olivier Lambotte (ORCID: https://orcid.org/0000-0003-4425-8516)
- Lambert Assoumou (ORCID: https://orcid.org/0000-0002-5547-1796)
- Mathilde Bertheau
- Raghiatou Baldé
- Cathia Soulié (ORCID: https://orcid.org/0009-0008-2032-4148)
Institutions
- Université Toulouse III - Paul Sabatier (FR)
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Aix-Marseille Université (FR)
- Université Paris-Saclay (FR)
- Sorbonne Université (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Intercommunal Aix-Pertuis (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre d'Immunologie et des Maladies Infectieuses (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Hôpital Sainte-Marguerite (FR)
- Bicêtre Hospital (FR)
- Hôpital Tenon (FR)
- THERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1136/jitc-2024-009728
- Citations
- 18
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.09
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Astellas Pharma
- CHIST-ERA